CALC CalciMedica Inc
Price (delayed)
$1.85
Market cap
$24.94M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.22
Enterprise value
$17.01M
CalciMedica, Inc., a clinical-stage biopharmaceutical company, focuses on the development of medicines for the treatment of diseases of the retina and optic nerve. The company's lead product candidate is GB-102,
Highlights
The quick ratio has soared by 82% YoY and by 31% from the previous quarter
CALC's equity has soared by 77% year-on-year and by 60% since the previous quarter
The EPS has soared by 84% YoY but it has contracted by 13% from the previous quarter
Key stats
What are the main financial stats of CALC
Market
Valuations
Earnings
Shares outstanding
13.48M
Market cap
$24.94M
Enterprise value
$17.01M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.73
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$24.2M
Net income
-$13.7M
EBIT
-$13.7M
EBITDA
-$13.64M
Free cash flow
-$21.15M
Per share
Balance sheet
Liquidity
EPS
-$1.22
EPS diluted
-$1.22
Free cash flow per share
-$1.88
Book value per share
$1.07
Revenue per share
$0
TBVPS
$1.76
Total assets
$19.79M
Total liabilities
$5.38M
Debt
$0
Equity
$14.41M
Working capital
$15.98M
Debt to equity
0
Current ratio
5.34
Quick ratio
5.07
Net debt/EBITDA
0.58
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-65.1%
Return on equity
-100.5%
Return on invested capital
-138.3%
Return on capital employed
-85%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
CALC stock price
How has the CalciMedica stock price performed over time
Intraday
-5.13%
1 week
-7.04%
1 month
-16.67%
1 year
-54.21%
YTD
-47.74%
QTD
-3.14%
Financial performance
How have CalciMedica's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$24.2M
Net income
-$13.7M
Gross margin
N/A
Net margin
N/A
CALC's net income has soared by 60% YoY
CALC's operating income is up by 36% year-on-year but it is down by 8% since the previous quarter
Growth
What is CalciMedica's growth rate over time
Valuation
What is CalciMedica stock price valuation
P/E
N/A
P/B
1.73
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has soared by 84% YoY but it has contracted by 13% from the previous quarter
CALC's equity has soared by 77% year-on-year and by 60% since the previous quarter
CALC's price to book (P/B) is 49% lower than its last 4 quarters average of 3.6 and 9% lower than its 5-year quarterly average of 2.0
Efficiency
How efficient is CalciMedica business performance
CalciMedica's return on assets has surged by 61% YoY and by 8% QoQ
The return on equity has surged by 57% year-on-year and by 11% since the previous quarter
The ROIC has grown by 13% from the previous quarter
Dividends
What is CALC's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for CALC.
Financial health
How did CalciMedica financials performed over time
The company's current ratio has surged by 85% YoY and by 29% QoQ
The quick ratio has soared by 82% YoY and by 31% from the previous quarter
The debt is 100% smaller than the equity
CALC's equity has soared by 77% year-on-year and by 60% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.